PRQR ProQR Therapeutics

ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer

ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer
EN
05/10/2020

Underlying

PRQRProQR Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ProQR Therapeutics

 PRESS RELEASE
Free
PRQR ProQR Therapeut...

ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline...

ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026 LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will host a virtual Investor and Analyst Event highlighting its pipeline entitled: “Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810” Ahead of the anticipated target engagement data for AX-0810 in the fi...

March 25, 2026 1 EN
 PRESS RELEASE
Free
PRQR ProQR Therapeut...

ProQR Announces Year End 2025 Operating and Financial Results

ProQR Announces Year End 2025 Operating and Financial Results Advancing AX-0810 through ongoing Phase 1 dosing, with target engagement data expected 1H 2026Selected Development Candidates AX-2402 for Rett syndrome (MECP2, R270X) and AX-2911 for MASH (PNPLA3)Ended 2025 with € 92.4 million cash and cash equivalents and achieved $4.5 million in Eli Lilly collaboration milestones in 2025, supporting runway into mid-2027 LEIDEN, Netherlands & CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through trans...

March 12, 2026 1 EN
 PRESS RELEASE
Free
PRQR ProQR Therapeut...

ProQR Announces Webcast of Presentation at the 2026 Citizens Life Scie...

ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference LEIDEN, Netherlands & CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that company management will present at the Citizens Life Sciences Conference on Wednesday, March 11, 2026 at 3:25pm ET. A live webcast and recording of this presentation will be available from the “Investors & Me...

March 3, 2026 1 EN
 PRESS RELEASE
Free
PRQR ProQR Therapeut...

ProQR Announces Planned Changes to Board Composition

ProQR Announces Planned Changes to Board Composition LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company’s next Annual General Meeting (AGM) as their terms conclude.  The planned changes to ProQR’s Board composition at its 2026 AGM reflect the...

February 9, 2026 1 EN
 PRESS RELEASE
Free
PRQR ProQR Therapeut...

ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Develo...

ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1 enrollment and dosing in healthy volunteers ongoing with target engagement data expected in H1 2026, followed by inclusion of a patient cohortDevelopment Candidates selected for pipeline programs AX-2402 for Rett syndrome (MECP2, R270X) and AX-2911 for MASH (PNPLA3)Strategic collaboration with Eli Lilly achieved $4.5 million in milestones in 2025, ...

January 8, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch